AC Immune SA - Company Profile

Powered by

All the sales intelligence you need on AC Immune SA in one solution.

$ $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how AC Immune SA fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with AC Immune SA.

Back to companies

AC Immune SA: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

AC Immune SA (AC Immune) is a clinical-stage biopharmaceutical company primarily engaged in the development of precision medicine for the diagnosis, treatment, and prevention of neurodegenerative diseases. The company's main activities involve leveraging its proprietary technology platforms, SupraAntigen and Morphomer, to develop a diverse pipeline of clinical and preclinical product candidates. These products are designed to target established and emerging neurodegenerative pathologies, with a focus on Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. The company collaborates with industry leaders such as Takeda, Janssen, Life Molecular Imaging, and Lilly to advance its proprietary programs. The company operates globally, with a significant presence in Switzerland and the US. AC Immune is headquartered in Lausanne, Switzerland.

 Gain a 360-degree view of AC Immune SA and make more informed decisions for your business Gain a 360-degree view of AC Immune SA and make more informed decisions for your business Learn more
Headquarters Switzerland
Address Epfl Innovation Park, Building B, Lausanne, 1015
Website www.acimmune.com
Telephone 41 21 3459121
No of Employees 122
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange ACIU (NASD)
Revenue (2025) $4.3M -86.9% (2025 vs 2024)
EPS XYZ
Net Income (2025) XYZ -38.4% (2025 vs 2024)
Market Cap* $255.5M
Net Profit Margin (2025) XYZ -957.5% (2025 vs 2024)
* As of and is in US$
View AC Immune SA financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Learn more

AC Immune SA premium industry data and analytics

40+

Catalyst Calendar

Proactively evaluate AC Immune SA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for AC Immune SA’s relevant decision makers and contact details.

20+

Pipeline Drugs

Identify which of AC Immune SA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Clinical Trials

Determine AC Immune SA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

10+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products
Pipeline
Crenezumab (anti-Abeta antibody)- Alzheimer’s Disease
ACI-24 (anti-Abeta vaccine)- Alzheimer’s Disease
XYZ
XYZ
XYZ
Understand AC Immune SA portfolio and identify potential areas for collaboration Understand AC Immune SA portfolio and identify potential areas for collaboration Learn more
Image for loader

Competitor Comparison

Key Parameters AC Immune SA Tillotts Pharma AG Idorsia Pharmaceutical Ltd Alector Inc Addex Therapeutics Ltd
Headquarters Switzerland Switzerland Switzerland United States of America Switzerland
City Lausanne Rheinfelden Allschwil South San Francisco Geneva
State/Province - Aargau Basel-Landschaft California -
No. of Employees 122 373 552 156 2
Entity Type Public Private Private Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Learn more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Learn more
Executives
Name Position Board Since Age
Andrea Pfeifer, Ph.D. Director; Chief Executive Officer Executive Board 2016 68
Christopher Roberts Chief Financial Officer Senior Management 2019 37
Piergiorgio Donati Chief Operating Officer Senior Management 2018 55
Martin Zügel Chairman Executive Board - 63
Monika Butler Vice Chairman Executive Board 2021 64
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into AC Immune SA key executives to enhance your sales strategy Gain insight into AC Immune SA key executives to enhance your sales strategy Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?